Need to Register?   Forgot Password?
You need to upgrade your Flash Player to view this content.

What's New?
    Modest CV benefit with ezetimibe/simvastatin in IMPROVE-IT. PCSK9 inhibitor alirocumab LDL reduction in statin intolerance in ODYSSEY. Slides available for download.
  • Expert blog: Robert Eckel, MD, on PCSK9 inhibitors
    In this interview, Dr Eckel comments on the potential role of PCSK9 inhibitors for unmet clinical needs in dyslipidemia
  • Case study: clinical application of the ACC/AHA cholesterol guidelines
    Join JoAnne Foody, MD, on an interactive journey toward primary prevention in a 48-year-old patient with LDL 150 and elevated ASCVD risk. Login required.
  • ACC/AHA lifestyle guidelines coverage
    Interactive summary recommendations & slides on the ACC/AHA lifestyle guidelines. Slides available for download in the slide library.
  • Dabigatran (Pradaxa) FDA Drug Safety Communication
    Lower risk for stroke and death, but higher risk for GI bleeding, seen with dabigatran vs warfarin among Medicare patients aged 65 or older. FDA has made no changes to Pradaxa labeling or recommendations for use. More here.
  • Not a member? What are you waiting for?
    Sign up now for exclusive access to downloadable slides and other content from CCMDweb.org. Registration is free and takes just a moment to complete.
  • CCMDweb.org: Professional Education
    for Cardiovascular Disease

    CCMDweb.org is a premier destination for professional education, clinically relevant information, and programs that augment knowledge and practice gaps in cardiovascular disease (CVD) with the goal of enhancing patient care. Since 1996, CCMD has partnered with preeminent thought leaders to educate US healthcare professionals on issues spanning the cardiovascular disease (CVD) spectrum—highlighting many cardiometabolic conditions that individually or collectively contribute to cardiovascular risk, including dyslipidemia, atherosclerosis, diabetes, stroke, inflammation, and obesity.

    A sample of the award-winning programs on CCMDweb.org:
    • Slide library with nearly 1,000 downloadable slides exploring cardiometabolic diseases
    • On-demand programs, including newsletters, case studies, and webcasts
    • Clinical guidelines resources
    • Expert commentaries on seminal research
    • Patient education handouts
    • And more!
    Registration is free and unlocks premium content offerings and incentives. Sign up here.

    CCMDweb.org is the official website of The Committee on Cardiovascular and Metabolic Diseases™ (CCMD™), a multi-component independent educational initiative offering programs and resources focused on the management of cardiovascular and metabolic diseases as a means to prevent or reduce global cardiovascular risk. Click here for more information about CCMD.
    In the News
    Data presented at VEITH Symposium show 30% increase in one-year success rates for vascular bypass surgery, and dramatic reduction in amputations
    Nov 24, 2014 -- Vascular Flow Technologies have presented study results at the 41st Annual VEITH Symposium on Vascular and Endovascular Issues in New York, showing a 30% increase in one-year success for...

    Preclinical studies of Cardioxyl's HNO prodrugs demonstrate effective treatment of chronic diastolic dysfunction and potential for oral administration
    Nov 24, 2014 -- Researchers testing Cardioxyl Pharmaceuticals, Inc. experimental HNO prodrugs presented data demonstrating that HNO improves cardiac function in animal models of diastolic heart failure, and...

    Copyright 2014 Medical News Today